J
Joel E. Gallant
Researcher at Johns Hopkins University
Publications - 66
Citations - 12492
Joel E. Gallant is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Viral load & Acquired immunodeficiency syndrome (AIDS). The author has an hindex of 31, co-authored 66 publications receiving 11848 citations. Previous affiliations of Joel E. Gallant include University of Zimbabwe & Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
Myron S. Cohen,Ying Q. Chen,Marybeth McCauley,Theresa Gamble,Mina C. Hosseinipour,Nagalingeswaran Kumarasamy,James Hakim,Johnstone Kumwenda,Beatriz Grinsztejn,José Henrique Pilotto,Sheela Godbole,Sanjay Mehendale,Suwat Chariyalertsak,Breno Santos,Kenneth H. Mayer,Irving F. Hoffman,Susan H. Eshleman,Estelle Piwowar-Manning,Lei Wang,Joseph Makhema,Lisa A. Mills,Guy de Bruyn,Ian Sanne,Joseph J. Eron,Joel E. Gallant,Diane V. Havlir,Susan Swindells,Heather J. Ribaudo,Vanessa Elharrar,David N. Burns,Taha E. Taha,Karin Nielsen-Saines,David D. Celentano,Myron Essex,Thomas R. Fleming +34 more
TL;DR: In this article, Antiretroviral therapy that reduces viral replication could limit the transmission of human immunodeficiency virus type 1 (HIV-1) in serodiscordant couples.
Journal ArticleDOI
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation
Florencia Pereyra,Xiaoming Jia,Paul J. McLaren,Amalio Telenti,de Bakker Pi,Bruce D. Walker,Stephan Ripke,Chanson J. Brumme,Sara L. Pulit,Mary Carrington,Carl M. Kadie,Jonathan M. Carlson,David E. Heckerman,Graham Rr,Robert M. Plenge,Steven G. Deeks,Gianniny L,Gabriel Crawford,Jean C. Sullivan,Elena Gonzalez,Davies L,Amy L. Camargo,Jamie Moore,Beattie N,Soumi Gupta,Crenshaw A,N P Burtt,Candace Guiducci,Namrata Gupta,Gao X,Qi Y,Yuko Yuki,Alicja Piechocka-Trocha,Emily Cutrell,Rachel Rosenberg,Kristin Moss,Lemay P,Jacqueline G. O'Leary,Schaefer T,Verma P,I Tóth,Brian L. Block,Brett Baker,Alissa C. Rothchild,Lian J,Jacqueline Proudfoot,Donna Marie Alvino,Seanna Vine,Marylyn M. Addo,Todd M. Allen,Marcus Altfeld,Matthew R. Henn,Le Gall S,Hendrik Streeck,David W. Haas,Daniel R. Kuritzkes,Gregory K. Robbins,Robert W. Shafer,Roy M. Gulick,Cecilia M. Shikuma,Richard Haubrich,Sharon A. Riddler,Paul E. Sax,Eric S. Daar,Heather J. Ribaudo,Brian K. Agan,Agarwal S,Ryan Ahern,Allen Bl,Altidor S,Altschuler El,Ambardar S,Kathryn Anastos,Brenna L. Anderson,Anderson,Andrady U,Antoniskis D,David R. Bangsberg,Barbaro D,Barrie W,Bartczak J,Barton S,Basden P,Nesli Basgoz,Suzane Bazner,Nicholas Bellos,Benson Am,Judith Berger,Bernard Nf,Bernard Am,Christopher E. Birch,Bodner Sj,Robert K. Bolan,Boudreaux Et,Meg Bradley,Braun Jf,Brndjar Je,Stephen J. Brown,Brown K,Sheldon T. Brown,Burack J,Bush Lm,Cafaro,Campbell O,Justin Campbell,Carlson Rh,Carmichael Jk,Casey Kk,Cavacuiti C,Celestin G,Stephen T. Chambers,Chez N,Lisa M. Chirch,Cimoch Pj,Daniel E. Cohen,Cohn Le,Brian Conway,David A. Cooper,Cornelson B,Cox Dt,Cristofano Mv,Cuchural G,Julie Czartoski,Dahman Jm,Jennifer S. Daly,Benjamin T. Davis,Kenneth L. Davis,Davod Sm,Edwin DeJesus,Craig A. Dietz,Dunham E,Dunn Me,Todd B. Ellerin,J. J. Eron,John Fangman,Farel Ce,Ferlazzo H,Sarah Fidler,Fleenor-Ford A,Frankel R,Kenneth A. Freedberg,French Nk,Jonathan D. Fuchs,Jon Fuller,Gaberman J,Joel E. Gallant,Rajesh T. Gandhi,Garcia E,Garmon D,J. Gathe,Gaultier Cr,Gebre W,Gilman Fd,Gilson I,Paul A. Goepfert,M. S. Gottlieb,Claudia Goulston,Groger Rk,Gurley Td,Haber S,Hardwicke R,W D Hardy,P. R. Harrigan,Trevor Hawkins,Sonya L. Heath,Frederick Hecht,Henry Wk,Hladek M,Hoffman Rp,James Horton,Hsu Rk,Gregory D Huhn,Peter W. Hunt,Hupert Mj,Illeman Ml,Hans Jaeger,Robert M. Jellinger,Mina John,Jennifer Johnson,Kristin Johnson,Johnson H,Kevin M. Johnson,Joly J,Wilbert C. Jordan,Carol A. Kauffman,Khanlou H,Killian Rk,Arthur Y. Kim,Kim Dd,Kinder Ca,Kirchner Jt,Laura Kogelman,Erna M. Kojic,Korthuis Pt,Kurisu W,Douglas S. Kwon,Melissa Lamar,Harry Lampiris,Lanzafame M,Michael M. Lederman,Lee Dm,Lee Jm,Lee Mj,Lee Et,Lemoine J,Jay A. Levy,Josep M. Llibre,Liguori Ma,Susan J. Little,Anne Y. Liu,Lopez Aj,Mona R. Loutfy,Loy D,Mohammed Dy,Man A,Michael K. Mansour,Vincent C. Marconi,Martin Markowitz,R. Marques,Jeffrey N. Martin,Hal Martin,Kenneth H. Mayer,MJ McElrath,McGhee Ta,Barbara H. McGovern,Katherine McGowan,McIntyre D,Mcleod Gx,Menezes P,Mesa G,Craig E. Metroka,Dirk Meyer-Olson,Miller Ao,Montgomery K,Karam Mounzer,Ellen H. Nagami,Nagin I,Nahass Rg,Nelson Mo,Nielsen C,Norene Dl,David H. O’Connor,Bisola O. Ojikutu,Jason F. Okulicz,Oladehin Oo,Oldfield Ec rd,Susan Olender,Mario A. Ostrowski,William F. Owen,Pae E,Parsonnet J,Pavlatos Am,Perlmutter Am,Pierce Mn,Pincus Jm,Pisani L,Price Lj,Laurie A. Proia,Prokesch Rc,Pujet Hc,Moti Ramgopal,Almas Rathod,Rausch M,Ravishankar J,Frank S. Rhame,Richards Cs,Douglas D. Richman,Rodes B,Rodriguez M,Rose Rc rd,Eric S. Rosenberg,Daniel I. Rosenthal,Ross Pe,Diana Rubin,Rumbaugh E,Saenz L,Michelle R Salvaggio,Sanchez Wc,Sanjana Vm,Steven Santiago,Schmidt W,Hanneke Schuitemaker,Sestak Pm,P. Shalit,Shay W,Shirvani Vn,Silebi Vi,Sizemore Jm,Paul R. Skolnik,Marcia Sokol-Anderson,James M. Sosman,Stabile P,Jack T. Stapleton,Starrett S,Stein F,Hans-Jürgen Stellbrink,Sterman Fl,Valerie E. Stone,David Stone,Giuseppe Tambussi,Randy Taplitz,Ellen Tedaldi,Theisen W,Ramon A. Torres,Tosiello L,Cécile Tremblay,Tribble Ma,Trinh Pd,Tsao A,Ueda P,Vaccaro A,Valadas E,Vanig Tj,Vecino I,Vega Vm,Veikley W,Wade Bh,Walworth C,Wanidworanun C,Doug Ward,Warner Da,Rainer Weber,Daniel P. Webster,Weis S,David Wheeler,D. White,Edmund Wilkins,Alan Winston,Wlodaver Cg,van't Wout A,Wright Dp,Otto O. Yang,Yurdin Dl,Zabukovic Bw,Kimon C. Zachary,Zeeman B,Zhao M +336 more
TL;DR: Differences in binding to viral peptide antigens by HLA may be the major factors underlying genetic differences between HIV controllers and progressors, and genome-wide association results implicate the nature of the HLA–viral peptide interaction as the major factor modulating durable control of HIV infection.
Journal ArticleDOI
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
Joel E. Gallant,Edwin DeJesus,Jose R. Arribas,Anton Pozniak,Brian Gazzard,Rafael Campo,Biao Lu,Damian J McColl,Steven L. Chuck,Jeffrey Enejosa,John J. Toole,Andrew K. Cheng +11 more
TL;DR: The combination of tenofovir DF and emtricitabineplus efavirenz fulfilled the criteria for noninferiority to a fixed dose of zidovudine and lamivudine plus efvirenz and proved superior in terms of virologic suppression, CD4 response, and adverse events resulting in discontinuation of the study drugs.
Journal ArticleDOI
Association between Adherence to Antiretroviral Therapy and Human Immunodeficiency Virus Drug Resistance
Ajay K. Sethi,David D. Celentano,Stephen J. Gange,Richard D. Moore,Richard D. Moore,Joel E. Gallant,Joel E. Gallant +6 more
TL;DR: A cumulative adherence of 70%-89%, a CD4 cell nadir of <200 cells/microL, and the missing of a scheduled clinic visit in the past month were independently associated with an increased hazard of viral rebound with clinically significant resistance.
Journal ArticleDOI
Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial
Beatriz Grinsztejn,Mina C. Hosseinipour,Heather J. Ribaudo,Susan Swindells,Joseph J. Eron,Ying Q. Chen,Lei Wang,San San Ou,Maija Anderson,Marybeth McCauley,Theresa Gamble,N. Kumarasamy,James Hakim,Johnstone Kumwenda,José Henrique Pilotto,Sheela Godbole,Suwat Chariyalertsak,Marineide Gonçalves de Melo,Kenneth H. Mayer,Susan H. Eshleman,Estelle Piwowar-Manning,Joseph Makhema,Lisa A. Mills,Ravindre Panchia,Ian Sanne,Joel E. Gallant,Irving F. Hoffman,Taha E. Taha,Karin Nielsen-Saines,David D. Celentano,Max Essex,Diane V. Havlir,Myron S. Cohen +32 more
TL;DR: The clinical benefits recorded, combined with the striking reduction in HIV-1 transmission risk previously reported, provides strong support for earlier initiation of antiretroviral treatment.